Pharmacist Cardiovascular | Stroke On-Demand 1h

This course dissects an article from the Journal of the American Medical Association – Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

While Direct Oral Anticoagulants (DOACs) such as apixaban and rivaroxaban are recommended for patients with atrial fibrillation, there hasn’t been evidence directly comparing them. Join us as we discuss their differences and guide your selection of a DOAC for minimized side effects and increased efficacy in your patients.

Learning Objectives

Upon successful completion of this application-based course, participants should be able to:
1. Describe key aspects of the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation Study.
2. Compare rates of hemorrhagic events between patients from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study.
3. Compare rates of ischemic events between patients from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study.
4. Evaluate limitations discussed in the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation Study.
5. Apply the findings from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study in providing care to patients with atrial fibrillation.

Faculty

Harriet Kusi, PharmD, BCPS

Clinical Pharmacist
MedStar Georgetown University Hospital

Disclosures:

Harriet Kusi has no relevant financial relationships with ineligible companies to disclose.

Course Details